BLRX:NSD-BioLineRx Ltd (USD)

COMMON STOCK | Biotechnology | NSD

Last Closing Price

USD 3.24

Change

+0.01 (+0.31)%

Market Cap

USD 0.15B

Volume

0.45M

Avg Analyst Target

USD 14.50 (+347.53%)

Avg User Target

USD
Average Analyst Rating

Verdict

Fundamental Analysis

Verdict

About

BioLineRx Ltd., a clinical-stage biopharmaceutical development company, focuses on oncology. Its development pipeline consists of clinical-stage therapeutic candidates, which include BL-8040, a peptide for the treatment of solid tumors, hematological malignancies, and stem cell mobilization; AGI-134, an immuno-oncology agent in the development for solid tumors; and BL-5010, a customized, proprietary, pen-like applicator for the non-surgical removal of skin lesions. The company has collaboration agreement with MSD for the cancer immunotherapy field; MD Anderson Cancer Center to investigate the combination of BL-8040 with KEYTRUDA (pembrolizumab) in pancreatic cancer; and Genentech Inc. to investigate the combination of BL-8040 for solid tumors. BioLineRx Ltd. was founded in 2003 and is headquartered in Hevel Modi'in, Israel.

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2021-08-02 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
MRNA Moderna, Inc

-6.99 (-1.98%)

USD141.98B 237.00 190.09
BNTX BioNTech SE

+11.86 (+3.61%)

USD79.30B 59.35 50.07
REGN Regeneron Pharmaceuticals, Inc

+2.52 (+0.44%)

USD61.22B 16.36 12.83
VRTX Vertex Pharmaceuticals Incorpo..

-3.26 (-1.62%)

USD52.23B 26.58 13.36
ALXN Alexion Pharmaceuticals, Inc

N/A

USD40.34B 59.23 42.56
GMAB Genmab A/S

+0.12 (+0.27%)

USD29.62B 33.28 3.77
BGNE BeiGene, Ltd

+10.83 (+3.42%)

USD29.25B N/A N/A
SGEN Seagen Inc

+0.85 (+0.55%)

USD27.91B 47.87 38.34
RPRX Royalty Pharma plc

-0.99 (-2.59%)

USD23.19B 31.49 13.92
ALNY Alnylam Pharmaceuticals, Inc

-0.98 (-0.55%)

USD21.03B N/A N/A

ETFs Containing BLRX

Symbol Name Weight Mer Price(Change) Market Cap

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Biotechnology)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 28.57% 81% B- 77% C+
Dividend Return N/A N/A N/A N/A N/A
Total Return 28.57% 81% B- 76% C
Trailing 12 Months  
Capital Gain 44.64% 76% C 62% D-
Dividend Return N/A N/A N/A N/A N/A
Total Return 44.64% 76% C 61% D-
Trailing 5 Years  
Capital Gain 325.76% 87% B+ 88% B+
Dividend Return N/A N/A N/A N/A N/A
Total Return 325.76% 87% B+ 88% B+
Average Annual (5 Year Horizon)  
Capital Gain 74.08% 85% B 90% A-
Dividend Return N/A N/A N/A N/A N/A
Total Return 74.08% 85% B 90% A-
Risk Return Profile  
Volatility (Standard Deviation) 146.23% 17% F 10% F
Risk Adjusted Return 50.66% 76% C 69% D+
Market Capitalization 0.15B 30% F 27% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 87%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Biotechnology)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio N/A N/A N/A N/A N/A
Price/Book Ratio 2.36 67% D+ 56% F
Price / Cash Flow Ratio -6.61 49% F 68% D+
EV/EBITDA N/A N/A N/A N/A N/A
Management Effectiveness  
Return on Equity -72.07% 39% F 23% F
Return on Invested Capital -65.76% 35% F 12% F
Return on Assets -20.59% 58% F 18% F
Debt to Equity Ratio 12.44% 52% F 69% D+
Technical Ratios  
Short Ratio 0.05 99% A+ 97% A+
Short Percent 0.21% 98% A+ 91% A-
Beta 1.66 33% F 22% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

No discussions yet

User / Independent Analyst Ratings

User Name Target Rating Target Horizon (Months) Target Price User Analysis Date Comment

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

What to not like:
Low market capitalization

This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.

High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector